XNAS · DWTX
-2.33% · -$0.0400 · Vol 116.3K
Market closed · last close 4:00 PM ET · price as of 17:19:24 ET
Dogwood Therapeutics, Inc. Common Stock

Dogwood Therapeutics, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$1.68
Card
Relationship Map

Follow $DWTX

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $DWTX by email

Veridion Score

BETALOW CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
DWTX
Dogwood Therapeutics, Inc. Common Stock
Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
Middle range · LOW confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5 of 6 factors measured · Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is DWTX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading DWTX catalysts
About Dogwood Therapeutics, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
8
Country
US

Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.74
Day high
$1.83
Day low
$1.60
Previous close
$1.72
52W high
$7.91
-78.76% from high
52W low
$1.34
5% of range
Market cap
$57.4M
EPS
$-17.1400
Beta
1.40
Shares out
34M
Volume
116.3K
1.60× rel vol
Avg volume
72.7K
VWAP
$1.77
Price history computed in-house
1W
-13.40%
1M
-32.53%
3M
+9.09%
1Y
-66.47%
YTD
-59.62%
SMA 50 $1.90 · below
SMA 200 $2.52 · below
52W position 5%

DWTX overview

Veridion Score
59
Registered · 2026-09-18
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around DWTX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading DWTX Form 4 filings
Public disclosures

Congress activity in DWTX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for DWTX in the cached public ledger.

Federal contracts

DWTX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for DWTX in this window.
Lobbying spend

DWTX lobbying filings, year to date.

Registered lobbying filings matched to Dogwood Therapeutics, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for DWTX in this window.
Loading news for DWTX
Analyst ratings
Sovereign unlock shows live analyst consensus for DWTX.
Options
Sovereign unlock shows live options positioning for DWTX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.